大唐药业(836433) - 2023 Q3 - 季度财报

Financial Performance - Operating revenue for the first nine months of 2023 reached CNY 148,221,522.62, representing a 20.38% increase from CNY 123,128,711.71 in the same period last year[10] - Net profit attributable to shareholders decreased by 47.81% to CNY 10,451,865.59 for the first nine months of 2023, down from CNY 20,026,659.14 in the previous year[10] - Total revenue for the first nine months of 2023 reached CNY 148,221,522.62, an increase from CNY 123,128,711.71 in the same period of 2022, representing a growth of approximately 20.4%[39] - Net profit for the first nine months of 2023 was CNY 10,451,865.59, compared to CNY 20,026,659.14 in the same period of 2022, reflecting a decrease of approximately 47.8%[41] - Total comprehensive income for the first nine months of 2023 was CNY 15.00 million, down from CNY 21.84 million in the same period of 2022[46] Cash Flow - Cash flow from operating activities showed a negative net amount of CNY -30,469,257.43, a significant decline compared to CNY 56,753,894.26 in the same period last year[10] - The net cash flow from operating activities was -15,516,350.45 CNY, a significant decrease compared to 55,825,114.18 CNY in the previous year[51] - Cash received from sales of goods and services was 156,227,171.15 CNY, a decrease from 170,793,514.23 CNY in the previous year[51] - The company reported a total cash outflow from operating activities of 198,417,681.04 CNY, compared to 128,230,328.50 CNY in the previous year[51] Assets and Liabilities - Total assets increased by 7.13% to CNY 692,224,366.46 as of September 30, 2023, compared to CNY 646,151,101.29 at the end of 2022[10] - The company's current assets totaled CNY 273,446,861.72, a decrease of about 11.3% from CNY 308,402,565.52 at the end of 2022[29] - Total liabilities increased to CNY 197,423,196.22 from CNY 163,510,076.69, reflecting a growth of approximately 20.7%[31] - Total liabilities increased to CNY 194,635,653.29 in the third quarter of 2023, compared to CNY 160,644,379.97 in the same period of 2022, marking an increase of approximately 21.1%[37] Inventory and Borrowings - Inventory increased by 43.64% to CNY 63,381,769.46, primarily due to an increase in stock of goods[11] - Short-term borrowings rose by 71.68% to CNY 121,786,501.73, driven by increased loans for purchasing raw materials[11] - Short-term borrowings surged to CNY 121,786,501.73, compared to CNY 70,938,192.59, representing an increase of about 71.6%[30] Income and Expenses - Operating costs increased by 36.93% to CNY 43,089,716.64, attributed to a rise in sales volume[12] - Cash paid for purchasing goods and services rose by 99.92% to CNY 67,546,430.59, driven by an increase in sales orders[13] - The company reported a significant increase in other income, which rose by 332.58% to CNY 1,643,944.60, mainly due to increased government subsidies received[12] - Investment income decreased by 73.70% to CNY 1,100,620.11, primarily due to a reduction in the amount of financial products held[12] Shareholder Information - The total number of ordinary shares at the end of the period is 258,790,681, with a decrease of 2,226,600 shares during the reporting period[18] - The largest shareholder, Renhe Real Estate Development Co., Ltd., holds 59.63% of the shares, with no change in their holdings[20] Government Subsidies - The company received increased government subsidies, resulting in a rise of 81.42% in deferred income, amounting to CNY 10,803,717.82[11] - The company's net profit for the year-to-date is CNY 10,451,865.59, a decrease of 47.81% compared to the previous year, primarily due to a government subsidy of CNY 10 million received in the same period last year[12] Research and Development - Research and development expenses for the first nine months of 2023 were CNY 5,213,689.86, slightly down from CNY 5,432,812.46 in the same period of 2022, indicating a decrease of about 4%[40] - The company plans to continue focusing on market expansion and new product development to drive future growth[46]